Direct Detection of SARS-CoV-2 from primary sample
For our customers, we have prepared the method of direct diagnostics of a novel coronavirus from respiratory samples without RNA extraction.
Direct detection of SARS-CoV-2 is based on lysis of real clinical material and enables the rapid detection by simplifying and shortening of the laboratory procedure.
The method applies for both our new products GeneProof SARS-CoV-2 PCR Kit, as well as the new GeneProof SARS-CoV-2 Screening PCR Kit. The both products also contain unique internal control (IC) consisted of enveloped nucleoprotein particle which completely imitates natural SARS-CoV-2 virus particle. These kits are the only SARS-CoV-2 diagnostics which really control all detection steps individually in each examined clinical specimen: lysis of virus envelope + lysis of virus nucleoprotein particle and viral RNA release + reverse transcription step + PCR amplification efficiency and inhibition. Moreover, both kits comprise of extremely robust components, which suppress the inhibitors' influence usually present in this kind of clinical samples.
Therefore, these two diagnostic kits are the only diagnostics which allow fully controlled direct SARS-CoV-2 RNA detection in clinical specimens.
The GeneProof company guarantees the functionality of direct detection of the transport medium PBS (Phosphate Buffered Saline). Furthermore, we are currently testing other transport media. Our support department is prepared to help you with validation.
GeneProof declaration, a protocol for direct detection and verification of using a transport medium are available on request.